Educational information only. Not medical advice. SafePeptideUse sells nothing and is not a substitute for a qualified clinician. Talk to a healthcare professional before making any health decision.
SafePeptideUse logoSafePeptideUse

KPV

Also known as Lysine-Proline-Valine, alpha-MSH (11-13) fragment

Not approved in the USAnti-inflammatory & immune

Last reviewed · Awaiting clinical review

Main safety concerns

Human evidence is limited and mostly from animal gut studies. Its safety record looks clean so far, but it has not been tested in long human trials.

Educational information, not medical advice. If you have symptoms that worry you, contact a clinician or emergency services.

What is known

A small anti inflammatory tripeptide from the tail of alpha-MSH, studied most for gut inflammation.

Status:
Not an FDA approved drug. FDA found no human safety data for it.[3] [4]
Strongest evidence for any claim:

See the evidence claim by claim

What it is and how it works

KPV is the last three amino acids of alpha-MSH, a natural hormone. Researchers found that this short tail keeps most of the anti inflammatory effect of the full hormone without the pigment or strong hormone signaling. It appears to calm inflammation from inside the cell, and it is taken up efficiently through a gut transporter called PepT1. It is the anti inflammatory part of the KLOW blend.[1]

Evidence by claim

Each claim is graded on its own. Tap a grade to see what it does and does not mean.

  • Reduces gut inflammation and related markers.

    Source type: Animal study

    The strongest area, with animal studies showing inflammatory markers cut roughly in half. No completed human dose finding trial.

  • Calms inflammation in skin and elsewhere.

    Source type: Animal study

    Supported by cell and animal work, with human use running ahead of the evidence.

  • Used for gut issues, skin flares, and general inflammation.

    No source cited for this claim.

Reported side effects

  • WarningUnknown long term risks, since there is no long term human safety data
  • CautionInjection site irritation(uncommon)[1]
  • InfoGenerally very well tolerated, with no skin darkening[1]Unlike its parent hormone alpha-MSH, KPV does not darken skin at usual doses.

Interactions and combination risks

  • InfoKLOW blend

    KPV is the anti inflammatory part of the KLOW blend, combined there with BPC-157, TB-500, and GHK-Cu.

Who should avoid it

  • SeriousPregnancy or breastfeeding

    No safety data in pregnancy or breastfeeding.

Dosing

Placed after the evidence and risks on purpose. Nothing here is a recommendation for you.

Community reported use, not tested in trials
Route(s)subcutaneous, oral (it is absorbed intact through a gut transporter)
Typical rangeInjectable: about 200 to 500 mcg per day, sometimes up to 1,000 mcg. Oral capsules are also used, often around 10 to 20 mg per day for gut targeted effects.
FrequencyOnce or twice daily
Cycle guidanceOften run for a few weeks.
NotesNo human dose finding trial sets an official dose. The blood is short, around 2 hours, so it does not build up. Oral KPV is used specifically for gut inflammation because it is absorbed intact.
[1]

For the equipment itself, see syringes, needles, and the rest of the kit.

Reconstitution

Vial sizes5 mg, 10 mg
DiluentBacteriostatic water for multi dose vials, or sterile water for single use
ConcentrationExample: a 5 mg vial plus 1 mL of water gives 5 mg/mL, so a 500 mcg dose is 0.1 mL, which is 10 units on a U-100 syringe.
NotesKPV usually ships as 5 mg or 10 mg freeze dried vials. Oral capsule forms also exist for gut use.

General reconstitution technique

Units and volume arithmetic

Converts between an amount and syringe units for the vial and diluent you enter. It starts empty and does not suggest an amount. Open the full calculator

Inputs

What do you want to convert?
  1. mg

    Total amount printed on the vial label.

    Sizes sold:
  2. mL

    Volume of bacteriostatic water already in the vial.

  3. Check the unit. 1 mg = 1,000 mcg, so the wrong one is a 1,000x error.

  4. U-100

    Printed on the syringe wrapper. Results over this size are shown as invalid.

Result

Fill in steps 1 to 3 to see the arithmetic. Nothing here is a suggested amount.

Settings live in the address bar, so a pasted link reopens this calculator as you left it.

Educational arithmetic only. It does not choose an amount for you and is not medical or dosing advice. Verify every calculation independently.

Storage and stability

Dry powder (lyophilized)

TemperatureFreeze for long term storage, or 2 to 8 short term
Shelf lifeMany months when frozen
NotesKeep dry and out of light until you mix it.

After mixing

Temperature2 to 8 (refrigerated)
Shelf lifeAbout 2 to 4 weeks
NotesDo not freeze after mixing. Discard if cloudy or discolored.

General storage and stability guide

COA and purity notes

Common adulterantsunderdosed or mislabeled vials, material sold without clear content
MislabelingAs with any research peptide, a recent third party COA helps confirm identity and purity.
NotesSold as unregulated research material, both as an injectable and as oral capsules.

How to read a COA

Sources

  1. [1]KPV ameliorates LPS-induced intestinal inflammation and mucosal barrier damage

    PMC (preclinical study) 2019 (opens source in a new tab)· Animal study
  2. [2]Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases

    Brzoska T, Luger TA, Maaser C, Abels C, Böhm M (Endocrine Reviews) 2008 (opens source in a new tab)· Review
  3. [3]FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23 to 24, 2026: KPV Related Bulk Drug Substances

    U.S. Food & Drug Administration 2026 (opens source in a new tab)· Regulatory record
  4. [4]Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

    U.S. Food & Drug Administration 2026 (opens source in a new tab)· Regulatory record

Last reviewed 8 July 2026 · editorial status: reviewed